Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (urothelial cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: lutikizumab, bermekimab | 0.81 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 7 Parkinson's papers of 1,708 | 0.73 |
| pathways Reactome | 7 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 6174
Sealed predictions
- IL1A in dopamine neurons, braak+0.17 (p 0.670) → -0.03 (p 0.947)receipt 6181
Swarm cases
receipt 6181: IL1A in dopamine neurons, braak
- power
- full sample +0.16 (p 0.538, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.18 (p 0.465, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.28 (p 0.265, n 18). could be the mix.
- skeptic
- leave-one-out range +0.05 to +0.28, sign flips 0; without severely affected donors +0.16 (p 0.538, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL1A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts